A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.

PHASE2CompletedINTERVENTIONAL

Enrollment

2,022

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions

Malaria

Interventions

BIOLOGICAL

RTS,S/AS02A

Trial Locations (1)

GSK Investigational Site, Maputo